Phase 1CompletedINTERVENTIONAL
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
ClinicalTrials.gov · NCT01373450 · Registry updated: 2015-09-02
- Condition / research focus
- Type 2 Diabetes Mellitus
- Sponsor
- Merck Sharp & Dohme LLC
- Countries with listed sites
- No country reported
- Registry dates and results
- Start: 2011-06. Completion: 2011-07 (may be estimated). Results are posted in this registry.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Oxyntomodulin (drug)
- Liraglutide 0.6 mg (drug) — also listed as: Victoza®
- Liraglutide 1.2 mg (drug) — also listed as: Victoza®
- Placebo for Oxyntomodulin (drug)
- Placebo for Liraglutide (drug)
Where the study takes place — 0 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.